Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PAK4 kinase activity and somatic mutation promote carcinoma cell motility and influence inhibitor sensitivity.

Oncogene - 18 Apr 2013

Whale A D, Dart A, Holt M, Jones G E, Wells C M

Abstract excerpt

Hepatocyte growth factor (HGF) and its receptor (c-Met) are associated with cancer cell motility and invasiveness. p21-activated kinase 4 (PAK4), a potential therapeutic target, is recruited to and activated by c-Met. In response, PAK4 phosphorylates LIM kinase 1 (LIMK1) in an HGF-dependent manner in metastatic prostate carcinoma cells. PAK4 overexpression is known to induce increased cell migration speed but the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptor Proteins, Signal Transducing
Share to Adenosine Triphosphate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to cdc42 GTP-Binding Protein

Share to Cell Movement

Share to Hepatocyte Growth Factor

Share to Lim Kinases

Share to p21-Activated Kinases

Share to Prostatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 22689056
DOI: 10.1038/onc.2012.233
PMCID: PMC3446866

Genes

PAK4
HGF
LIMK1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PAK4 kinase activity and somatic mutation promote carcinoma cell motility and influence inhibitor sensitivity.PMID 22689056Read ↗

Therapeutic Potential of Targeting PAK SignalingSemantic proximity Read ↗

Therapeutically actionable PAK4 is amplified, overexpressed and involved in bladder cancer progressionSemantic proximity Read ↗

Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer—Opportunities, Challenges, and LimitationsSemantic proximity Read ↗

The Novel Phosphatase Domain Mutations Q171R and Y65S Switch PTEN from Tumor Suppressor to Oncogene.Semantic proximity Read ↗

Emerging functions of p21‐activated kinases in human cancer cellsSemantic proximity Read ↗

Modulation of p21-activated kinase 1 alters the behavior of renal cell carcinoma.Semantic proximity Read ↗

MET∆14 promotes a ligand-dependent, AKT-driven invasive growthSemantic proximity Read ↗

TLK1-MK5 axis drives prostate cancer cell motility and pathologic features of aggressivenessSemantic proximity Read ↗

Functional characterization of PIK3CA E545A mutation in MCF-7 breast cancer cells reveals enhanced proliferation and resistance to Alpelisib.Semantic proximity Read ↗

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer modelsSemantic proximity Read ↗

PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.Semantic proximity Read ↗

Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.